MOBILE

"Modelling, Optimization and Control of Biomedical Systems"

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙782˙925 €
EC contributo	1˙782˙925 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2008-AdG
Funding Scheme	ERC-AG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-01-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Mr. Nome: Shaun Cognome: Power Email: send email Telefono: +44 20 7594 8773 Fax: +44 207 594 8609	UK (LONDON)	hostInstitution	1˙782˙925.00
2	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Prof. Nome: Efstratios Cognome: Pistikopoulos Email: send email Telefono: +44 207 5946620 Fax: +44 207 5941129	UK (LONDON)	hostInstitution	1˙782˙925.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The main aim of the proposed project is to develop models and model based control and optimization methods and tools for drug delivery systems, which would ensure: (i) Reliable and fast calculation of the optimal drug dosage without the need for an on-line computer while taking into account the specifics and constraints of the patient model (personalised health care) (ii) Flexibility to adapt to changing patient characteristics, (iii) Incorporation of the physician s performance criteria (iv) Safety of the patients (v) Reduced size effects by optimising the drug infusion rates The overall control and optimisation approach will rely on the novel multi-parametric model-based control technology developed by the PI over the past 15 years, which will be further extended and implemented in the context of the following biomedical systems (a) insulin delivery (b) control of anaesthesia and hemodynamic variables, (c) optimal chemotherapy design for anti-cancer (d) optimal control of the chemotherapy for HIV.'